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The current Ebola epidemic has presented challenges both medical and ethical. Although we have known
epidemics of untreatable diseases in the past, this particular one may be unique in the intensity and rapidity of its
spread, as well as ethical challenges that it has created, exacerbated by its geographic location. We will look at the
infectious agent and the epidemic it is causing, in order to understand the ethical problems that have arisen.
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The current Ebola epidemic has presented challenges
both medical and ethical. Although we have known epi-
demics of untreatable diseases in the past, this particular
one may be unique in the intensity and rapidity of its
spread, as well as ethical challenges that it has created, ex-
acerbated by its geographic location. We will look at the
infectious agent and the epidemic it is causing, in order to
understand the ethical problems that have arisen.The infection
Ebola Virus Disease is caused by one of at least 30 known
RNA viruses capable of causing a viral hemorrhagic fever
syndrome. The genus Ebolavirus is currently classified
into five separate subspecies: Sudan, Zaire, Tai Forest
(Ivory Coast), Reston, and Bundibugyo ebolavirus. Wild an-
imals serve as a reservoir and can transmit the virus to
humans. It is thought to be endemic in the wild fruit bat.
Humans can acquire the virus by eating “bushmeat” such
as antelope or monkeys that have been infected. The virus
is transmitted in body fluids, primarily blood, saliva, em-
esis or stool and does not appear to be transmitted
through the air. Caregivers of infected patients, and those
who prepare them for burial, are at particular risk. Of con-
cern are the recent reports that the virus is showing gen-
etic mutations, even during the current epidemic.Correspondence: G.Kevin.Donovan@georgetown.edu
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unless otherwise stated.With the African derived Ebola virus infections, there
is an incubation period that can last from three days to
three weeks. The virus is not spread until the patient be-
comes symptomatic. Patients develop fever, chills, head-
ache, muscle aches, vomiting and diarrhea. In the later
stages they develop a hemorrhagic rash, and bleeding
from any mucous membranes. Currently there is no ap-
proved specific therapy available for treatment, and no
available vaccines for prevention. Intensive general med-
ical support is critical to survival, with IV fluid therapy
and control of bleeding disorders. This care must be
given with strict attention to barrier isolation from the
contaminated fluids from the patient. Such intensive
care provides the best likelihood of survival for an in-
fected patient. Current mortality rates in this epidemic
are at about 55%, and have ranged as high as 90% in pre-
vious epidemics with minimal medical support. Protect-
ive barriers for healthcare workers (gloves, gowns, masks
and goggles) should be worn for identified Ebola cases.
However, identification may be delayed because the early
symptoms can resemble malaria, typhoid fever, cholera,
and other illnesses which present much more commonly
in the geographic region [1].The epidemic
The current epidemic of Ebola virus disease is one of two
dozen outbreaks since discovery of the virus in 1976. It
was identified along the border of Guinea and Sierra
Leone last March, subsequently spreading to Liberia, with
a handful of cases in Nigeria associated with the arrival of
an infected airline passenger [2]. Although EVD in Nigeria. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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contacts of the symptomatic airline passenger, the epi-
demic continues to proliferate in Guinea, Sierra Leone,
and Liberia, with cases now reported in Senegal as well.
This has become the largest Ebola outbreak ever, be-
cause of the perfect storm of circumstances.
Despite multiple outbreaks in the past, this epidemic is
the first to have a major impact on multiple large cities,
making it harder to contain than those previous instances
in rural areas. It has occurred in the poorest of African
countries. They had insufficient infrastructure to mount
an adequate response: the few hospitals are largely without
adequate equipment, protective barrier clothing, intraven-
ous fluids for the patients, or toilets, many of them with
dirt floors.
The cultural and political atmosphere also presents
significant challenges for those trying to contain the epi-
demic. After years of civil war and brutality, there is no
trust of the government institutions, nor is there trust of
the medical system. Some deny that Ebola is real, even go-
ing so far as to claim that there is no epidemic, but the
government health workers are killing patients to simulate
an epidemic and receive Western funding. Traditional
burial practices include hand-washing of the body and
large wakes, so families refuse cremation of Ebola victims
or even funerals that would allow infection protection
such as body bags. Those who are ill stay away from the
hospitals for fear of becoming infected with Ebola; those
who have Ebola hide to avoid stigmatization. Finally, these
countries have among the lowest ratio of physicians and
nurses per population in the world, some 200 times less
than found in the United States or Canada [3].
Nevertheless, the world took little note that despite
these overwhelming challenges West African healthcare
workers have been at the front lines since the beginning of
the epidemic. They have experienced by far the most in-
fections and the most fatalities among those responding to
the epidemic. Only now are we seeing hesitation from
local healthcare workers fearful of showing up at hospitals
with insufficient gowns and gloves, etc. to protect them.
Their fear is not unjustified; this epidemic is averaging a
55% fatality rate with no specific treatments or preventa-
tive vaccines yet available.
The current epidemic finally came to widespread at-
tention in the rest of the world when it was announced
that two American medical missionaries were infected.
Dr. Kent Brantley and Nancy Writebol of the charitable
organization SIM were treated with an experimental
therapy, Z Mapp, then transferred to an isolation ward
at Emory medical school in Atlanta for further support-
ive therapy, and both subsequently survived. The world
and the region had known little of this unapproved
medication until their treatment nor did people realize
at the time how few doses were available [4]. In fact,Dr. Brantley asked that it be given first to his colleague
in case there wasn’t enough for both of them. The sce-
nario was repeated with a Spanish priest who became in-
fected caring for Ebola patients, was brought back in
Spain where a Z Mapp dose was given to him, but he died.
Following questions of why it wasn’t provided to Africans,
it was revealed that it had been available for the doctor
who had been leading Sierra Leone’s battle against the
Ebola outbreak. The treatment team, from Doctors with-
out Borders and the World Health Organization, agonized
through the night and ultimately decided not to try the
drug. The doctor, Sheikh Umar Khan, died a few days
later, on July 29. Subsequently Liberian doctors received
doses of the same medication, reportedly the last available,
and one physician has subsequently died.
Meanwhile, the virus has spread, with over 9,000 re-
ported cases (and projected to go as high as a million) and
a continued 55% mortality rate. Ineffective measures have
been taken, such as restricting air travel and quarantining
neighborhoods, as well as more sensible actions such as
screening air passengers for symptoms, increasing public
health measures with isolation of patients, protective bar-
rier clothing, supportive medical care and diagnostic labs,
and safe burial practices. Despite these measures, and an in-
flux of health volunteers and government health workers
from other countries, with the support of Doctors Without
Borders, the Red Cross, and WHO, the number of cases is
projected to increase for many months, rising as high as
20,000. Trials of potential vaccines and curative treatments
have begun, but can’t produce any effective and verifiable
results for many months or longer.
Discussion
Ethical questions
Should untested experimental treatments be offered in
this epidemic?
We must, of course, consider the pros and cons of giving
experimental drugs to people. These are drugs that had
never been tested in human subjects before they were given
to the sick patients, therefore, the dangerous and adverse
effects can neither be known nor safely predicted. It is en-
tirely possible they may be ineffective or even harmful. In
America, all FDA approved studies must go through a first
stage where the likelihood of harm can first be assessed,
followed by subsequent phases to look for additional side
effects and evidence of efficacy. So far these therapies have
been tested only on a handful of monkeys, and not even
the first phase had occurred for human beings.
So far, six people have received one candidate experi-
mental therapy, Z Mapp. Two of them have died. This
doesn’t prove that it’s effective, and it doesn’t prove that
it’s safe. We don’t know what harms it may do long-term
or even short-term, and the guiding principle of the use of
any new medicine is “in the first place, do no harm”.
Donovan Philosophy, Ethics, and Humanities in Medicine 2014, 9:15 Page 3 of 4
http://www.peh-med.com/content/9/1/15Research is designed to answer questions about possible
harms and possible effectiveness, but what has been done
here is not research, but rather it is scary experimental
treatment. It was done because Ebola is a scary deadly dis-
ease. But if we were to keep approaching it in this uncon-
trolled way, we may never know if these therapies are safe
and effective, or at least not know until a great deal of
harm might occur. The world, especially that part of the
world now suffering most from Ebola, desperately needs
to know if there can be an effective treatment, as well as
an effective prevention in the form of vaccine. We owe it
to all possible victims, current and potential, to get this
right. There have been examples in the past of untested
and under tested therapies being rushed into service, and
ultimately doing the patients a disservice. Some of these
misadventures occurred on the African continent, leading
to a pervasive distrust of Western drug companies using
Africans as their experimental “guinea pigs”.
On August 11, 2014, the World Health Organization
convened a panel to discuss these ethical issues [3].
Their response was widely reported: “It is ethical to offer
unproven interventions with as yet unknown efficacy and
adverse effects, as potential treatment or prevention”.
What received less attention were their qualifiers: the
statement applied to “the particular circumstances of this
outbreak,” and emphasized the “ethical criteria… includ-
ing transparency, informed consent, freedom of choice,
confidentiality, respect for autonomy and involvement of
the community” which must guide the provision of such
interventions. Moreover, “if and when they are used to
treat patients, there is a moral obligation to collect and
share all data generated” and “there was unanimous agree-
ment that there is a moral duty to also evaluate these in-
terventions in the best possible clinical trials under the
circumstances in order to definitively prove their safety
and efficacy or provide evidence to stop their utilization”.
This has been my constant position, and it remains so.
When considering the allocation of scarce resources, the
most pressing question is: who should be treated?
The simple answer is that although the question is ethic-
ally very important and complex, it will remain moot until
therapies are made available. As we have seen, no tested
or approved therapy exists. The remaining stock of experi-
mental therapies is currently exhausted. So, the short an-
swer to “who should be treated?” reverts back to “who can
be treated, and how?” To do the most good for the most
people affected means to do our best supportive therapy
for patients, public health, containment measures for the
population, and protective barriers, particularly for the
healthcare workers and caretakers on the front line. These
are the scarce resources that can be allocated immediately,
and must be supplied immediately in order to control this
epidemic as soon as possible. Experimental therapies andvaccine trials, as important as they are, cannot be ready
for field testing within weeks, but more likely quite a few
months or longer, and if successful, even longer until they
can be employed on a large scale [5].
Given that the few doses that were on hand had been used,
was it unethical to give them to the American healthcare
workers and a Spanish, missionary priest first?
The answer to this can serve to guide the eventual alloca-
tion decisions when such interventions are finally ready. I
would contend that an argument can be made that we
owe a duty to those workers who have knowingly placed
themselves at risk of disease and death in order to serve
the needs of others. That duty to first responders is not
just to Americans or Europeans, but to the great number
of Africans as well, who continue to place themselves in
harm’s way, even after record numbers of healthcare
workers have been infected and have died in this Ebola
epidemic. Their actions reflect the highest altruistic ideals
of the medical profession.
Moreover, there is a practical reason to consider treat-
ing healthcare workers first. It serves the interests of the
majority of patients to keep medical workers and care-
takers alive and in the field. It also increases the likeli-
hood that others may be willing to come and help them,
if they don’t believe they would be sent to the back of
the line or stranded should they succumb to infection.
And, finally, healthcare workers might be the ones most
likely to accept enrollment in trials of these medications,
and understand the requirements of informed consent
in the treatment, study, given the widespread misinfor-
mation and mistrust regarding Western clinical trials by
a large number of Africans.Should Americans, Canadians and Europeans who are
exposed or infected be brought home while Africans are
left behind to die?
This is one of the most troubling aspects of sending for-
eign volunteers to help the medical crisis. It seems unjust
that Africans, including African healthcare workers, do
not have all the life-saving advantages of Westerners.
There is clearly inequity here, but it is not the fault of the
doctors, nurses and other healthcare workers who came
from their countries to help in Africa. It is the intrinsic in-
equity of the world in which the goods of society are dis-
tributed unevenly. If we were to reverse the question, and
ask that foreign volunteers should be required to stay and
suffer the consequences of an inadequate healthcare sys-
tem which they are only trying to help, it would perpetu-
ate another kind of injustice. Moreover, the consequence
would be to discourage those who are willing to come and
help, thereby increasing the disadvantage to those natives
of the African countries.
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since 1976, why is there no preventative vaccine for
effective therapy?
Since it first appeared on the scene, there have been
nearly 2 dozen outbreaks of Ebola virus disease, “yet the
world was woefully unprepared for the current tragedy,
with no licensed vaccines or treatments” [6]. This in part
reflects the arduous process of developing therapeutic
medications. Nevertheless, this could have been accom-
plished in the past four decades. Other forces are clearly
at work here. The stark reality is that pharmaceutical
companies are in the business of producing therapies
that people will pay for, in order to support the stagger-
ingly expensive cost of research. As awful as the Ebola
virus is, it has caused far fewer deaths than malaria, tuber-
culosis, or even diarrheal diseases. Therefore, the sad truth
is Ebola represents a small and unrewarding market. Gov-
ernments often intervene in such situations to help and
protect their citizens. In this case, we are dealing with
some of the poorest countries on earth, without the funds
to provide a minimally decent healthcare system, much
less specialized therapies and vaccines. If people were to
spread to more developed countries, a greater push for ef-
fective interventions might have been demanded, leading
to the odious suspicion that the world cared less when the
problem is confined to poor African countries. Perhaps
the size and rapidity of this epidemic will have led to pub-
licity that pricks the conscience of the developed world, if
not to help our brothers, then at least to protect ourselves.
Conclusion
What have we learned?
The current outbreak of Ebola Viral Disease has reached
epidemic proportions as a result of a perfect storm of
conditions: It is a rapidly transmissible, untreatable, and
often fatal disease; it has increased exponentially after
reaching urban areas; it has spread in the poorest of
countries with already inadequate health staffing and fa-
cilities. Further, and larger outbreaks of this disease were
predictable, but little was done to prevent or prepare for
it. These are the truly crucial ethical issues. Secondary but
important issues focus on the use of untested and experi-
mental therapies and their just distribution, and further
dissemination when additional therapies and vaccine can-
didate are produced. These issues, coupled to the frighten-
ing nature of this disease, served to focus the attention of
the developed world on the epidemic in the third world.
Now we can best serve the needs of those affected by
doing what can help immediately: supplying personal pro-
tective barriers, personnel to staff hospitals, laboratories,
and cooperation with the governments and health systems
of the affected countries. This is the more immediate and
immediately achievable goal and should be the prime
focus of our ethical and humanitarian concern [7].The ideas put forth in this editorial, while focused upon
the impact of Ebola, call forth other perspectives on the
ethical questions, problems, and possible answers relating
to the often delicate balance and frequent in balance of
scientific, technical, and medical capabilities – and power
differential – spawned by differing economies, sociologies
and political cultures of developed and developing nations.
We anticipate additional contributions to this discussion
from other perspectives in the near future.
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